Marketing Cymbalta Case Study Case Study

Length: 7 pages Subject: Sports - College Type: Case Study Paper: #29988377 Related Topics: Sports Marketing, Net Present Value, Fda, Medicare And Medicaid
Excerpt from Case Study :

Eli Lilly


Eli Lilly is searching for a successor to Prozac, which is marketed as an antidepressant. They began with five major candidates, but are presently focused on Cymbalta, which is more of a pain medication. However, it is believed that there is a link between pain and depression. The issue is that the link is not universally recognized, and this leaves the company in a position of trying to decide how it wants to market the new drug. It could market it as an antidepressant that approaches the issue from a pain perspective, or it could market it for the relief of chronic pain, without any real focus on antidepressant capabilities.

Both approaches have their merits. Eli Lilly is undertaking this initiative to replace Prozac, which has allowed it to dominate the antidepressant business for the duration of that drug's patent. With patent protection set to expire, the company is now going to face significant competition from generics. The key for Lilly is not that it needs to replace its anti-depressant drug, it is that it needs to replace that revenue stream. It just so happens that the company has specifically targeted the antidepressant business for its new drug. It set up a task force to find this drug, and narrowed the list down to five candidates. The most promising of these is Cymbalta, and the group is now trying to figure out the best to market that drug.


1. The first approach is to market Cymbalta against other antidepressants. The apparent advantage of this approach is that the drug is clearly differentiated. Antidepressants do not typically have pain relief components, so Cymbalta would be approach depression from an entirely different perspective. That could potentially give it competitive advantage if the marketplace buys into this.

The other approach is to go against other pain medications. Cymbalta has some advantage there, in that it is a newer drug that has proven effective. There are disadvantages, however, in that it does not target a new niche, but rather seeks to compete in an old one. The link between pain and depression is downplayed here. The attractiveness of this option, which on the surface has fewer advantages, is that the pain market is bigger than the antidepressant market. It is more competitive as well, but if Cymbalta can become established this is going to be good with respect to replacing the Prozac revenue. Targeting the osteoporosis market, for example, would give the produce access to 20 million patients -- and growing.

A third option that was floated with the pursue FDA approval for the use of Cymbalta to treat fibromyalgia or DPNP. These are rarer conditions, so the market is not as big for drugs that treat these. DPNP, however, can relate from diabetes, and that is a big market. These markets are perhaps less competitive, but again pursuing a niche pain market is perhaps more limiting than the general approach, even if targeting a big condition like diabetes.

2. There are several factors that can adversely affect each strategy. The first factor is the size of the market. Each alternative has a different target market. FDA approval is typically for one specific use, so it is important to understand the market ramifications of each option prior to seeking regulatory approval. The size of the market has to be considered on the gross market size level, but also versus the competition. This requires an analysis of how well the company thinks Cymbalta can do in any given market. The potential total market will then be weighed against the cost of bringing the drug to market.

Costs are another issue. The regulatory process may be different depending on what ailment the drug is being sought for. It is believed, for example, that DPNP will be the fastest with respect to regulatory approval because there is no current treatment on the market. By getting to market more quickly Lilly can start earning before Prozac goes generic, or shortly thereafter. In another market, approval could take that much longer. While it is not always a great idea to take the short-term money, the timing of the cash flows matters when doing a net present value calculation on each of these options.


The drug can be used to treat a number of things, but the FDA needs to see efficacy in order to give its approval. The marketing team will not be able to determine if one of these alternatives is more or less likely to succeed, but the pharmacological team should know. The odds of gaining approval is another important consideration because it affects the expected net present value of the decision. A drug with 50% chance of final approval is not as useful as a drug with 90% chance, even if the 50% treatment has a bigger market.

The competition also matters. For example, to treat DPNP there is no competition. This means that Cymbalta would expect to see a domination of that market if it proves to be effective. In the generic pain market, there is a lot of competition. Low priced NSAIDs, for example, are a common means of dealing with pain. This means that it will be difficult to convince people to give up their current pain medications. Where it serves as an alternative to addictive pain medications, there is opportunity but ultimately this pathway will bring about significant competition and it is unclear how many competitive advantages Cymbalta has, or if those advantages would be enough to win much of the general pain business.

3. There are several threads of market research that would need to be conducted. On the patient side, it is important to understand the size of the market, and what its characteristics are. The size is probably the easiest to determine. The characteristics begin with demographics, but the study should go deeper. First, does a given condition's demographics have the insurance needed to pay for the drug? This will start to determine the actual market size. Another issue is the matter of polypharmacy. If Cymbalta is going to win customers from other painkillers, the marketing team should understand contraindications and the relevance that they play. If too many people who would otherwise be in the target market would have contraindications for other drugs they are taking, then they can be ruled out of the target market. Information like this can help to determine how much of the potential target market is realistic. The size of the market is important because the company also needs to have an advertising strategy. A very large potential market might make advertising easier because mass market ads can work. More specialized conditions require more focused marketing. The efficiency of the marketing -- the cost to acquire a new customer -- is an important variables, in particular if there is reason to believe that there might be constraints on the prices.

The physicians are going to be a major target market. At the end of the day, patients have low information. While a few might actually research drugs, most do not, and simply accept what their physician tells them. As such, it is important for the company to understand what barriers physicians might have with respect to prescribing Cymbalta. To understand that requires some market research to determine the likelihood -- in principle -- of a physician prescribing this drug. It is important to remember that there are strict prohibitions against Lilly marketing for off-label uses. Even if it wants to know if doctors would consider an off-label use, it should steer clear of asking that.

Lastly, payers matter. These are usually government (Medicare, Medicaid) or private insurance companies. The payers are high information customers, and they determine whether they will cover a specific drug. If they choose not to, then that will constrain the potential market for the drug. In the case of a government payer, that constraint could be substantial. Medicare is a major payer for some conditions, but Medicare likes to cut costs. As an example, if Lilly gets the impression that it will be unable to sell Medicare and Medicaid on Cymbalta for pain because there are cheaper options, this will be a market impediment. Sometimes those payers need to be convinced -- for example arguing that Cymbalta is less addictive -- but this is definitely something that has to be taken into consideration. If there are no big payers, then whether or not patients and physicians like the drug is not going to matter much.

4. Success for Eli Lilly is whatever option best replaces the Prozac income stream. Prozac has a great brand, which will help it avoid the nastiest of drop-offs once generics hit the market, but there will be a decline. The key for Lilly is to replace that income stream. But the company has to take a long-term view, and do a proper estimate for each…

Cite this Document:

"Marketing Cymbalta Case Study" (2016, April 29) Retrieved January 27, 2022, from

"Marketing Cymbalta Case Study" 29 April 2016. Web.27 January. 2022. <>

"Marketing Cymbalta Case Study", 29 April 2016, Accessed.27 January. 2022,

Related Documents
FDA and the Fifth Amendment
Words: 1441 Length: 4 Pages Topic: Medicine Paper #: 68534280

Pharmaceutical Law Perhaps one of the greatest ethical challenges of pharmaceutical marketing will be a result of overreach of the Justice Department with respect to its interpretation of the First Amendment. Indeed, in his dissenting opinion in Sorrell v. IMS Health, Inc., Justice Breyer argued, "If the Court means to create constitutional barriers to regulatory rules that might affect the content of a commercial message, it has embarked upon an unprecedented